Literature DB >> 9070183

The impact of complications after vascular surgery in Veterans Affairs Medical Centers.

A Kazmers1, L Jacobs, A Perkins.   

Abstract

The impact of perioperative complications on clinical outcomes and resource utilization was assessed for 8702 veterans who, during fiscal years 1991-1994, underwent vascular surgery procedures in DRGs 110 and 111, which include aortic and peripheral aneurysm repairs as well as renal artery and some peripheral vascular reconstructions. In-hospital mortality rate was 6.2% (537/8702). Mortality was 9.8% with any ICD-9-CM-coded complication vs 4.9% without (P < 0.001). Mortality was 28.9% in those with both cardiac and pulmonary complications, 11.0% with either cardiac or pulmonary complications, and 3.7% with neither cardiac nor pulmonary complications. Length of stay (LOS) was 25.8 +/- 21.9 days with any ICD-9-CM-coded complication vs 18.9 +/- 14.1 days without (P < 0.001). Further, RIS (Resource Intensity Scale), a measure of intensity of resource utilization, was greater in those with (3.01 +/- 0.81) vs without (2.76 +/- 0.70; P < 0.001) a complication. Pulmonary complications impacted LOS and RIS more adversely than cardiac. A logistic regression model of mortality indicated that increasing age [odds ratio (OR) 1.065], arrhythmia (OR 1.31), pneumonia (OR 2.52), surgical complications of the heart (OR 2.8), respiratory insufficiency (OR 4.75), stroke (OR 5.48), MI (OR 5.78), and acute renal failure (ARF, OR 9.58) were associated with increasing likelihood for death, whereas treatment in the largest, academically affiliated VAMCs (RPM 5) was associated with reduced mortality (OR 0.795). Increasing age, treatment in the largest affiliated (RPM 5) hospitals, arrhythmia, MI, CHF, any ICD-9-CM-coded complication, acute renal failure, respiratory insufficiency, pneumonia, and stroke progressively increased LOS by linear regression analysis, whereas surgical complications of the heart and postoperative death reduced LOS. Complications after vascular surgery have an adverse impact on perioperative mortality, length of stay, and utilization of resources.

Entities:  

Mesh:

Year:  1997        PMID: 9070183     DOI: 10.1006/jsre.1996.4946

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Renoprotective and Immunomodulatory Effects of GDF15 following AKI Invoked by Ischemia-Reperfusion Injury.

Authors:  Jing Liu; Sanjeev Kumar; Andreas Heinzel; Michael Gao; Jinjin Guo; Gregory F Alvarado; Roman Reindl-Schwaighofer; A Michaela Krautzberger; Pietro E Cippà; Jill McMahon; Rainer Oberbauer; Andrew P McMahon
Journal:  J Am Soc Nephrol       Date:  2020-02-07       Impact factor: 10.121

2.  Fenofibrate pre-treatment suppressed inflammation by activating phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signaling in renal ischemia-reperfusion injury.

Authors:  Feng-Jie Yang; Yong-Hua He; Jian-Hua Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-02-12

3.  Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia.

Authors:  K K Donnahoo; X Meng; L Ao; A Ayala; B D Shames; M P Cain; A H Harken; D R Meldrum
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

4.  ATF3 protects against renal ischemia-reperfusion injury.

Authors:  Takumi Yoshida; Hidekazu Sugiura; Michihiro Mitobe; Ken Tsuchiya; Satsuki Shirota; Sayoko Nishimura; Shunji Shiohira; Hiroshi Ito; Kiyoshi Nobori; Steven R Gullans; Takashi Akiba; Kosaku Nitta
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

5.  Novel resveratrol analogues attenuate renal ischemic injury in rats.

Authors:  Adam Khader; Weng-Lang Yang; Michael Kuncewitch; Jose M Prince; Philippe Marambaud; Jeffrey Nicastro; Gene F Coppa; Ping Wang
Journal:  J Surg Res       Date:  2014-08-13       Impact factor: 2.192

6.  The Effect of Autophagy on Inflammation Cytokines in Renal Ischemia/Reperfusion Injury.

Authors:  Haibin Ling; Hongguang Chen; Miao Wei; Xiaoyin Meng; Yonghao Yu; Keliang Xie
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

7.  Clinical Results of Endovascular Abdominal Aortic Aneurysm Repair in Patients with Renal Insufficiency without Hemodialysis.

Authors:  Atsushi Guntani; Jyun Okadome; Eisuke Kawakubo; Ryoichi Kyuragi; Kazuomi Iwasa; Ryota Fukunaga; Sosei Kuma; Takuya Matsumoto; Jin Okazaki; Yoshihiko Maehara
Journal:  Ann Vasc Dis       Date:  2012

8.  Dexamethasone ameliorates renal ischemia-reperfusion injury.

Authors:  Sanjeev Kumar; David A Allen; Julius E Kieswich; Nimesh S A Patel; Steven Harwood; Emanuela Mazzon; Salvatore Cuzzocrea; Martin J Raftery; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-09-24       Impact factor: 10.121

9.  Administration of dexamethasone protects mice against ischemia/reperfusion induced renal injury by suppressing PI3K/AKT signaling.

Authors:  Jiong Zhang; Ying Yao; Fang Xiao; Xiaoqin Lan; Chong Yu; Ying Zhang; Cao Jiang; Juan Yang; Guangchang Pei; Yueqiang Li; Song Rong; Shuang Hu; Junhua Li; Gang Xu
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

10.  Aloperine Protects Mice against Ischemia-Reperfusion (IR)-Induced Renal Injury by Regulating PI3K/AKT/mTOR Signaling and AP-1 Activity.

Authors:  Shuang Hu; Yuxing Zhang; Meng Zhang; Yanchao Guo; Ping Yang; Shu Zhang; Sakine Simsekyilmaz; Jun-Fa Xu; Jinxiu Li; Xudong Xiang; Qilin Yu; Cong-Yi Wang
Journal:  Mol Med       Date:  2015-11-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.